預測性臨床生物標記市場規模、佔有率和成長分析：按生物標記類型、臨床應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球預測性臨床生物標記市場價值為 72 億美元，預計到 2033 年將從 2025 年的 79.6 億美元成長到 178.3 億美元，預測期（2026-2033 年）的複合年成長率為 10.6%。

全球預測性臨床生物標記市場主要受分子診斷和個人化醫療融合的驅動，從而能夠更準確地預測治療反應和疾病進程。預測性生物標記是重要的生物學指標，可用於識別能夠從特定治療中獲益並最大限度地減少副作用的患者，並最佳化臨床試驗設計。該市場涵蓋診斷開發商、製藥公司和醫療服務提供者。基因組學、蛋白質組學和生物資訊學的最新進展正在革新這些工作流程，腫瘤靶向診斷就是一個典型的例子。此外，高通量定序和液態生物檢體技術至關重要，它們提高了檢測的靈敏度和擴充性。這些創新正在推動伴隨診斷的需求，並促進學術界和臨床實踐之間的策略合作，從而實現可操作的突變檢測並提高靶向臨床試驗的效率。

全球預測性臨床生物標記市場促進因素

全球預測性臨床生物標記市場的主要促進因素之一是對個人化醫療日益成長的需求。隨著醫療保健轉向更個人化的治療方案，對能夠預測治療反應和疾病進展的精準生物標記的需求變得至關重要。基因組學和蛋白​​質組學的進步推動了這一趨勢，使得識別和檢驗能夠指導治療決策的生物標記成為可能。此外，慢性病盛行率的上升以及人們對早期診斷和預防醫學日益成長的興趣也推動了對生物標記研究的投資，從而促進了預測性臨床應用領域的市場成長和創新。

全球預測性臨床生物標記市場的限制因素

全球預測性臨床生物標記市場的主要限制因素之一是監管核准和臨床應用的挑戰。嚴格的監管評估流程可能會延遲新型生物標記的引入，並阻礙其及時應用於臨床。此外，證明臨床效用和成本效益的複雜性也使得醫療專業人員難以接受這些生物標記。而且，生物標記在不同人群中的表現差異限制了其普適性，加劇了臨床醫生的疑慮，並可能阻礙其在個人化醫療中的廣泛應用。這些謹慎的態度阻礙了市場成長和創新。

全球預測性臨床生物標記市場趨勢

全球預測性臨床生物標記市場正顯著轉向人工智慧驅動的患者分層，利用先進的機器學習技術分析基因組學、蛋白質組學和臨床影像數據。這項創新旨在根據獨特的風險特徵和預期治療反應對患者群體進行分類，從而增強個人化治療策略並提高臨床試驗的有效性。隨著診斷檢查室和醫療保健系統擴大採用這些技術，專注於模型的可解釋性、臨床檢驗以及與醫療保健工作流程的無縫整合至關重要，這有助於建立信任並確保應用的可行性。此外，資料科學家、臨床醫生和監管機構之間的跨學科合作對於開發可靠且可操作的生物標記至關重要，這將推動市場快速成長和轉型。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球預測性臨床生物標記市場規模：按生物標記類型分類

• 基因生物標記
• 蛋白質體學生物標記
• 代謝體學物標誌物
• 轉錄組生物標記
• 表觀遺傳生物標記
• 多組體學物標誌物
• 其他

全球預測性臨床生物標記市場規模：依臨床應用分類

• 腫瘤學
• 心血管疾病
• 神經病變
• 感染疾病
• 自體免疫疾病
• 代謝性疾病
• 呼吸系統疾病
• 其他

全球預測性臨床生物標記市場規模：按最終用戶分類

• 醫院和診所
• 診斷檢查室
• 製藥和生物技術公司
• 學術研究機構
• 受託研究機構（CRO）

全球預測性臨床生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Danaher Corporation
• Merck KGaA
• PerkinElmer, Inc.
• Bio-Techne Corporation
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Guardant Health, Inc.
• Foundation Medicine, Inc.
• NeoGenomics, Inc.
• Abbott Laboratories
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings

結論與建議

Global Predictive Clinical Biomarkers Market size was valued at USD 7.2 Billion in 2024 and is poised to grow from USD 7.96 Billion in 2025 to USD 17.83 Billion by 2033, growing at a CAGR of 10.6% during the forecast period (2026-2033).

The global market for predictive clinical biomarkers is significantly driven by the integration of molecular diagnostics and personalized medicine, allowing for enhanced forecasting of therapeutic responses and disease trajectories. Predictive biomarkers serve as essential biological indicators for identifying patients who may benefit from certain treatments while minimizing adverse effects, thus optimizing clinical trial designs. The market includes diagnostics developers, pharmaceutical sponsors, and healthcare providers. Recent advancements in genomics, proteomics, and bioinformatics have revolutionized these workflows, exemplified by targeted diagnostics in oncology. Furthermore, high-throughput sequencing and liquid biopsy technologies are pivotal, offering heightened sensitivity and scalability. These innovations facilitate actionable mutation detection and improve the efficiency of targeted trials, thereby increasing demand for companion diagnostics and encouraging strategic partnerships within academia and clinical practice.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Predictive Clinical Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Predictive Clinical Biomarkers Market Segments Analysis

Global predictive clinical biomarkers market is segmented by biomarker type, clinical application, end user and region. Based on biomarker type, the market is segmented into Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Transcriptomic Biomarkers, Epigenetic Biomarkers, Multi-Omics Biomarkers and Others. Based on clinical application, the market is segmented into Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Autoimmune Diseases, Metabolic Disorders, Respiratory Diseases and Others. Based on end user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Predictive Clinical Biomarkers Market

One of the key market drivers for the Global Predictive Clinical Biomarkers Market is the increasing demand for personalized medicine. As healthcare shifts toward more individualized treatment plans, the need for precise biomarkers that can predict treatment responses and disease progression becomes crucial. This trend is propelled by advancements in genomics and proteomics, which enable the identification and validation of biomarkers that can guide therapeutic decisions. Furthermore, the rising prevalence of chronic diseases and the growing focus on early diagnosis and preventive care are also stimulating investments in biomarker research, thereby driving market growth and innovation in predictive clinical applications.

Restraints in the Global Predictive Clinical Biomarkers Market

One significant market restraint for the global predictive clinical biomarkers market is the challenges related to regulatory approvals and integration into clinical practice. The rigorous evaluation processes imposed by regulatory bodies can delay the introduction of novel biomarkers, hindering their timely availability for clinical use. Additionally, the complexity of demonstrating clinical utility and cost-effectiveness complicates the acceptance of these biomarkers among healthcare professionals. Furthermore, variability in biomarker performance across different populations may limit their generalizability, creating skepticism among clinicians and potentially impeding widespread adoption in personalized medicine approaches. This cautious mindset poses a barrier to market growth and innovation.

Market Trends of the Global Predictive Clinical Biomarkers Market

The Global Predictive Clinical Biomarkers market is experiencing a significant shift towards AI-driven patient stratification, harnessing advanced machine learning techniques to analyze genomic, proteomic, and clinical imaging data. This innovation seeks to categorize patient populations based on unique risk profiles and probable responses to therapies, thereby enhancing personalized treatment strategies and improving the effectiveness of clinical trials. As diagnostic laboratories and healthcare systems increasingly adopt these technologies, a strong focus on model interpretability, clinical validation, and seamless integration into healthcare workflows is critical for building trust and ensuring practical applications. Additionally, cross-disciplinary collaboration among data scientists, clinicians, and regulatory bodies is vital for the development of reliable, actionable biomarkers, positioning the market for rapid growth and transformation.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Predictive Clinical Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Transcriptomic Biomarkers
• Epigenetic Biomarkers
• Multi-Omics Biomarkers
• Others

Global Predictive Clinical Biomarkers Market Size by Clinical Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Autoimmune Diseases
• Metabolic Disorders
• Respiratory Diseases
• Others

Global Predictive Clinical Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Global Predictive Clinical Biomarkers Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Clinical Application, End User)
  • US
  • Canada
• Europe (Biomarker Type, Clinical Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Clinical Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Clinical Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Clinical Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations